Log in

Cambrex Stock Price, News & Analysis (NYSE:CBM)

$59.58
+0.07 (+0.12 %)
(As of 10/22/2019 07:31 AM ET)
Today's Range
$59.52
Now: $59.58
$59.64
50-Day Range
$59.50
MA: $59.67
$60.07
52-Week Range
$33.80
Now: $59.58
$60.29
Volume302,404 shs
Average Volume518,701 shs
Market Capitalization$2.01 billion
P/E Ratio21.51
Dividend YieldN/A
Beta2.19
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP13201110
Phone201-804-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$532.09 million
Cash Flow$3.91 per share
Book Value$19.48 per share

Profitability

Net Income$92.41 million

Miscellaneous

Employees1,732
Market Cap$2.01 billion
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.


Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) posted its quarterly earnings data on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.05. The biotechnology company had revenue of $152.05 million for the quarter, compared to analyst estimates of $132.78 million. Cambrex had a net margin of 9.41% and a return on equity of 8.20%. Cambrex's quarterly revenue was up 13.0% on a year-over-year basis. During the same period last year, the firm posted $0.76 EPS. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Cambrex.

What price target have analysts set for CBM?

5 brokerages have issued 12 month target prices for Cambrex's stock. Their predictions range from $43.00 to $60.00. On average, they expect Cambrex's stock price to reach $52.40 in the next year. This suggests that the stock has a possible downside of 12.1%. View Analyst Price Targets for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.

Has Cambrex been receiving favorable news coverage?

Press coverage about CBM stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cambrex earned a media sentiment score of -3.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for Cambrex.

Are investors shorting Cambrex?

Cambrex saw a decrease in short interest in September. As of September 30th, there was short interest totalling 1,110,000 shares, a decrease of 9.0% from the August 30th total of 1,220,000 shares. Based on an average daily volume of 694,300 shares, the days-to-cover ratio is presently 1.6 days. Approximately 3.3% of the shares of the company are short sold. View Cambrex's Current Options Chain.

Who are some of Cambrex's key competitors?

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), Gilead Sciences (GILD), NVIDIA (NVDA), CVS Health (CVS), Juno Therapeutics (JUNO), Intel (INTC), Western Digital (WDC) and Under Armour (UAA).

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. James G. Farrell, VP & Corp. Controller (Age 52)

Who are Cambrex's major shareholders?

Cambrex's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (0.26%), Confluence Investment Management LLC (0.21%), State of Alaska Department of Revenue (0.08%), Strs Ohio (0.05%), Assenagon Asset Management S.A. (0.04%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

Which institutional investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Confluence Investment Management LLC, Envestnet Asset Management Inc. and Nisa Investment Advisors LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

Which institutional investors are buying Cambrex stock?

CBM stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, State of Alaska Department of Revenue and Assenagon Asset Management S.A.. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $59.58.

How big of a company is Cambrex?

Cambrex has a market capitalization of $2.01 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.

What is Cambrex's official website?

The official website for Cambrex is http://www.cambrex.com/.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  266 (Vote Underperform)
Total Votes:  544
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: S&P 500 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel